Fundraising Fox

ExSight Ventures β€” Full Portfolio

22 tracked investments Β· listed companies and verified rows first

ONL Therapeuticsonltherapeutics.cominMar 2023βœ“ verified

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.

BiotechHealthtechMedical DevicesAnn Arbor, US

David Zacks(Co-Founder & Chief Scientific Officer)inDavid Esposito(Executive Officer, Director)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in

BoardAaron Fletcher(Director)in

Co-investorsInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more

Trefoil Therapeuticstrefoiltherapeutics.cominβœ“ verified

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.

BiotechHealthtechMedical DevicesSan Diego, US

David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in

BoardChristy Shaffer(Director)inRalph Bradshaw(Director)

Co-investorsHatteras Venture PartnersSolasta VenturesAccess BiotechnologyBios PartnersCorrelation VenturesFemHealth Ventures+2 more

2C Tech2ctechcorp.com

HealthtechIrvine, US

JAMES TAYLOR(Executive Officer)IRVING ROBERT ARMSTRONG(Executive Officer)ROBERT SHIMIZU(Executive Officer)NARESH MANDAVA(Director)

BoardAKITERU FURUKAWA(Director)CLAUDE BENEDICT(Director)

Co-investorsInFocus Capital Partners, LLC

Ajoajo.com
BioMedbiomedcentral.comin𝕏

BioMed Central is an academic publisher of open access, peer-reviewed scientific journals, including titles such as Algorithms for Molecular Biology covering bioinformatics and molecular biology research.

BiotechMedia & Entertainment

DTx Pharmadtxpharma.comin𝕏acquired by Novartis

The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.

BiotechHealthtechSan Diego, US

Arthur T Suckow(Executive Officer)inArthur Suckow, Ph.D.(Founder)in

Co-investorsAccess BiotechnologyRA CapitalJanus Henderson Investors

ELIOS Visioneliosvision.comin𝕏

Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.

Envisionen-vision.co.jp

A Japanese manufacturer and seller of billiard equipment, including cues, tips, and chalk, serving players and retailers worldwide through overseas distributors across 25+ countries.

Advanced ManufacturingConsumerHiroshima, JP

Masato Hiraoka(Chairman)Kazumi Kuwahara(President)

Co-investorsD CapitalGIC

Envision DiagnosticsOct 2019

Reinventing the eye exam with binocular OCT-based diagnostic technology.

Torrance, US

Richard Castro(Executive Officer)Alexander Walsh(Executive Officer, Director)Patrick Welsh(Director)Patrick Walsh(Director)Paul Updike(Executive Officer)

Horizonsurgicalsystemshorizonsurgicalsystems.comin

Horizon Surgical Systems develops surgical robotics for ophthalmic procedures, with a focus on improving cataract surgery.

AI & Machine LearningHealthtechMedical DevicesRobotics

Jacob Rosen(Founder)in

KINGSkingsofafrica.infoin𝕏

Springer is an academic and scientific publisher with a portfolio of over 2,700 journals and more than 220,000 books, serving researchers, authors, readers, and institutions worldwide.

Media & Entertainment

Co-investorsChanzo Capital

LensGenlensgen.comMay 2017

LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia.

BiotechHardwareHealthtechMedical DevicesIrvine, US

Ramgopal Rao(Founder & Chief Executive Officer)

BoardAkiteru Furukawa(Director)Michael Colaco(Director)Shivbir Grewal(Director)

Lwwlww.com

Co-investorsLightstone Ventures

NOVAInovai.co.ukJan 2023

Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesReading, GB

Prof. Francesca Cordeiro(Founder, Director & Chief Executive Officer)Prof. M. Francesca Cordeiro(Founder & CEO)MARIA FRANCESCA CORDEIRO(Director)

BoardNATALIE PANKOVA(Director)KARL DAVID KEEGAN(Director)STEPHEN ROY PAGE(Director)

Co-investorsAnglia Capital GroupInBC Investment Corp.Zinc

Oisois.netin𝕏

OIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians.

BiotechHealthtechMedical Devices

Quraqura.biz
Re-vanarevanatx.com

Co-investorsClarendon Fund Managers Ltd.Visionary Ventures

RetroSense Therapeuticsacquired by Allergan

First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.

BiotechAnn Arbor, US

Sean Ainsworth(Executive Officer, Director)

BoardTerry Cross(Director)Kenneth Kousky(Director)Cam Gallagher(Director)George Lasezkay(Director)

Co-investorsBoston Harbor AngelsGREAT LAKES BAY VENTURESanten Pharmaceutical

RevOpsis TherapeuticsSep 2025

BiotechSpringfield, US

Ramanath Bhandari(Executive Officer)Jeff Olson(Director)

BoardRam Palanki(Director)

Thumbnail for Constellation Pharmaceuticalsin𝕏

BiotechHealthtech

Co-investorsClal Biotechnology IndustriesLongitude CapitalTachyon VenturesThe Column Group

Valitorvalitorbio.cominOct 2022

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.

BiotechMedical DevicesBerkeley, US

Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)

BoardDrew Lanza(Director)in

Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect BioventuresExSight

Vanavana.org𝕏Nov 2022 Β· $11.9M

Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.

AI & Machine LearningData & Infrastructure

Art Abal(Founder)

Co-investorsAbstract VenturesAlphaLab CapitalCaladanEarl Grey CapitalParadigmSCB 10X+7 more

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.